| Literature DB >> 30077942 |
Connor J Kinslow1, Steven D Shapiro2, Michael F Grunebaum3, Eliza C Miller4.
Abstract
Concurrent use of modafinil or armodafinil with monoamine oxidase inhibitors (MAOIs) is contraindicated due to a theoretical risk of drug synergism and acute hypertensive episodes. However, few data are available to substantiate that risk, and several case studies have suggested that the combination is safe. To our knowledge, we present the first case of a patient treated concurrently with armodafinil and tranylcypromine. The patient developed an acute hypertensive crisis with severe headache, nausea, blurry vision, and neck stiffness. Her symptoms corresponded with the predicted pharmacokinetic and pharmacodynamic response. She was also taking brexpiprazole, which could have contributed to her underlying symptoms. However, limited data suggest that the single combination of brexpiprazole with armodafinil or MAOIs would be safe. Upon review of the literature, two out of seven patients, including our own, treated concurrently with modafinil or armodafinil and an MAOI developed an adverse reaction. Physicians should exercise caution if using these classes of drugs together.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30077942 PMCID: PMC6446082 DOI: 10.1016/j.jns.2018.07.023
Source DB: PubMed Journal: J Neurol Sci ISSN: 0022-510X Impact factor: 3.181